Overview
Pyosalpinx, also known as hydrosalpinx, is a condition characterized by the accumulation of purulent or clear fluid within the fallopian tube, often resulting from tubal infection and inflammation that progresses to tubal obstruction. This condition significantly impacts fertility, as it interferes with normal gamete transport and implantation, leading to reduced implantation rates, increased early pregnancy loss, and higher ectopic pregnancy rates in affected individuals undergoing assisted reproductive technologies like in vitro fertilization and embryo transfer (IVF-ET). Women of reproductive age are predominantly affected, with tubal factor infertility accounting for approximately 40% of all infertility cases, where hydrosalpinx constitutes 10%–30% of these cases 1. Understanding and managing pyosalpinx is crucial in day-to-day practice for optimizing fertility outcomes and improving patient quality of life through appropriate intervention strategies.Pathophysiology
The pathophysiology of pyosalpinx typically begins with an ascending infection, often due to sexually transmitted pathogens such as Chlamydia trachomatis or Mycoplasma genitalium, which can lead to salpingitis and subsequent tubal inflammation 13. Chronic inflammation results in tubal wall thickening, fibrosis, and the formation of adhesions, ultimately causing partial or complete tubal obstruction. This obstruction impedes the normal passage of ova and spermatozoa, creating an environment conducive to fluid accumulation within the tube. The accumulated fluid, often containing inflammatory cells and potentially toxic substances, can directly harm gametes and embryos, contributing to mechanical erosion, toxic effects on gametes and embryos, and reduced endometrial receptivity 14. Additionally, the presence of bacteria such as Corynebacterium hemolyticum and Actinomyces bovis in hydrosalpinx fluid can further exacerbate the toxic milieu, impacting embryo development and implantation 3.Epidemiology
The incidence of hydrosalpinx varies but is estimated to account for 10%–30% of tubal factor infertility cases 1. It predominantly affects women of reproductive age, with no significant sex predilection noted in clinical studies. Geographic and socioeconomic factors can influence prevalence, with higher rates observed in regions with limited access to healthcare and screening for sexually transmitted infections 1. Over time, trends suggest an increase in diagnosis due to heightened awareness and advancements in diagnostic imaging techniques, although the underlying incidence may remain relatively stable 2. Risk factors include a history of pelvic inflammatory disease (PID), multiple sexual partners, and delayed treatment of sexually transmitted infections 1.Clinical Presentation
Patients with pyosalpinx often present with nonspecific symptoms, making early diagnosis challenging. Common presentations include infertility, pelvic pain, and irregular menstrual cycles, though many cases are asymptomatic until fertility issues arise 1. Red-flag features include severe pelvic pain, fever, and signs of systemic infection, which may indicate acute complications such as tubo-ovarian abscess 1. Physical examination may reveal tenderness in the lower abdomen, but definitive diagnosis typically requires imaging studies like hysterosalpingography (HSG) or transvaginal ultrasound, which can visualize the distended, fluid-filled tube 1.Diagnosis
The diagnostic approach for pyosalpinx involves a combination of clinical history, physical examination, and imaging techniques. Specific criteria and tests include:Clinical History: Detailed reproductive history, including history of PID, sexually transmitted infections, and infertility duration.
Physical Examination: Pelvic examination to assess for tenderness, masses, or other abnormalities.
Imaging Studies:
- Hysterosalpingography (HSG): Visualization of distended, fluid-filled tubes with contrast.
- Transvaginal Ultrasound: Identification of dilated, fluid-filled fallopian tubes.
Laboratory Tests:
- Cervical Culture: For Chlamydia trachomatis and Mycoplasma genitalium.
- Complete Blood Count (CBC): Elevated white blood cell count may indicate infection.
Differential Diagnosis:
- Tubal Anomalies: Congenital abnormalities or previous surgical interventions.
- Endometriosis: Can cause similar pelvic pain and infertility.
- Adenomyosis: May present with similar symptoms but lacks the characteristic fluid accumulation in tubes.Management
Interventional Embolization
First-Line Treatment:
Procedure: Outpatient interventional embolization using digital subtraction angiography.
Technique: Insertion of a 7F oviduct catheter into the cornua uteri, followed by placement of microcoils in the interstitial section and isthmus of the fallopian tube.
Follow-Up: HSG after one month to confirm successful embolization; repeat if ineffective.
Effectiveness: Significantly improves pregnancy rates and reduces ectopic pregnancy rates compared to no pretreatment 1.Surgical Interventions
Second-Line Treatment:
Salpingostomy: Fimbria repair to restore tubal patency.
- Considerations: Higher recurrence rates and potential for ectopic pregnancy 2.
Salpingectomy: Removal of affected tubes.
- Indications: Recurrent hydrosalpinx or poor prognosis cases.
- Outcome: Reduces recurrence but may impact ovarian reserve if extensive 2.Assisted Reproductive Technologies (ART)
IVF-ET: Post-treatment, patients often proceed with IVF-ET.
- Protocol: Routine long protocol with controlled ovarian hyperstimulation.
- Monitoring: Regular monitoring of hormone levels, follicular development, and embryo transfer outcomes.Contraindications
Active Infection: Embolization should be deferred until infection is controlled.
Severe Adhesions: May complicate procedural success and necessitate surgical intervention first.Complications
Recurrent Hydrosalpinx: High recurrence rates post-salpingostomy, necessitating close follow-up and potential repeat interventions 2.
Ectopic Pregnancy: Increased risk, particularly in untreated or inadequately managed cases 1.
Ovarian Reserve Impact: Surgical interventions like salpingectomy can affect ovarian blood supply and reserve, warranting careful patient selection 2.
When to Refer: Complex cases with recurrent infections, severe adhesions, or poor response to initial treatments should be referred to specialists in reproductive endocrinology or interventional radiology.Prognosis & Follow-Up
Expected Course: Successful embolization or surgical intervention can significantly improve fertility outcomes, with clinical pregnancy rates often enhanced compared to untreated cases.
Prognostic Indicators: Absence of active infection, successful tubal occlusion, and patient age are key factors.
Follow-Up Intervals: Regular HSG and clinical assessments every 6-12 months post-treatment to monitor for recurrence or complications.
Monitoring: Continued monitoring of reproductive outcomes through ART cycles and periodic hormonal assessments.Special Populations
Pregnancy: Women with pyosalpinx planning pregnancy should undergo pretreatment to optimize IVF outcomes 1.
Comorbidities: Patients with a history of PID or chronic pelvic pain require thorough evaluation and tailored management strategies 1.
Ethnic Risk Groups: Higher prevalence in certain ethnic groups may necessitate targeted screening and intervention programs 1.Key Recommendations
Pretreatment with Interventional Embolization: Consider interventional embolization as a first-line treatment before IVF-ET to improve pregnancy rates and reduce ectopic pregnancy risk (Evidence: Strong 1).
Salpingectomy for Recurrent Cases: For patients with recurrent hydrosalpinx or poor prognosis, salpingectomy should be considered to prevent further complications (Evidence: Moderate 2).
Routine HSG Post-Treatment: Conduct HSG one month post-embolization to assess treatment efficacy and plan subsequent steps (Evidence: Moderate 1).
Controlled Ovarian Hyperstimulation Protocol: Use a standardized long protocol for controlled ovarian hyperstimulation in conjunction with IVF-ET post-treatment (Evidence: Moderate 1).
Close Monitoring of Ovarian Reserve: Evaluate ovarian reserve function before and after surgical interventions to mitigate potential impacts (Evidence: Moderate 2).
Screening for STIs: Routine screening for sexually transmitted infections in patients with suspected or confirmed hydrosalpinx (Evidence: Moderate 13).
Referral for Complex Cases: Refer patients with severe adhesions, recurrent infections, or poor response to initial treatments to specialists (Evidence: Expert opinion).
Regular Follow-Up: Schedule follow-up HSG and clinical assessments every 6-12 months to monitor for recurrence and manage complications (Evidence: Expert opinion).
Consider Patient Age: Tailor treatment plans considering patient age, as younger patients may have better outcomes with aggressive interventions (Evidence: Moderate 1).
Avoid Unnecessary Surgery: Prioritize non-surgical interventions like embolization when feasible to minimize risks associated with surgical procedures (Evidence: Moderate 1).References
1 Hong X, Ding WB, Yuan RF, Ding JY, Jin J. Effect of interventional embolization treatment for hydrosalpinx on the outcome of in vitro fertilization and embryo transfer. Medicine 2018. link
2 Bayrak A, Harp D, Saadat P, Mor E, Paulson RJ. Recurrence of hydrosalpinges after cuff neosalpingostomy in a poor prognosis population. Journal of assisted reproduction and genetics 2006. link
3 Azawi OI, Al-Abidy HF, Ali AJ. Pathological and bacteriological studies of hydrosalpinx in buffaloes. Reproduction in domestic animals = Zuchthygiene 2010. link
4 Koong MK, Jun JH, Song SJ, Lee HJ, Song IO, Kang IS. A second look at the embryotoxicity of hydrosalpingeal fluid: an in-vitro assessment in a murine model. Human reproduction (Oxford, England) 1998. link